Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy

Area of Science:

• Oncology
• Biotechnology
• Nanomedicine

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis.
• TNBC lacks specific molecular targets (ER, PR, HER2), complicating targeted therapy.
• Current treatments like chemotherapy face challenges of drug resistance and recurrence.

Purpose of the Study:

• To review advances in nanomaterial- and nanobiomaterial-based siRNA delivery platforms for TNBC therapy.
• To explore targeted therapy approaches for key genes, proteins, and transcription factors (TFs) in TNBC.
• To highlight the potential of siRNA-based therapies for improving TNBC prognosis and reducing mortality.

Main Methods:

• Review of recent scientific literature on siRNA delivery systems for TNBC.
• Discussion of targeted approaches utilizing nanomaterials for gene silencing in TNBC.
• Analysis of bioengineered siRNA drugs for simultaneous gene downregulation.

Main Results:

• Nanomaterial-based siRNA delivery platforms show promise for targeted TNBC therapy.
• Targeting upregulated genes, proteins, and TFs in TNBC can disrupt pathways associated with poor prognosis.
• Simultaneous gene silencing via bioengineered siRNA can significantly reduce TNBC progression.

Conclusions:

• siRNA-based therapies, particularly when delivered via nanomaterials, represent a promising frontier for TNBC treatment.
• Targeted gene silencing offers a strategy to overcome limitations of current TNBC therapies.
• Advances in nanomedicine are crucial for developing effective and less toxic treatments for aggressive breast cancers.